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Abstract
Bronchiectasis represents the final pathway of several infectious, genetic, immunologic or allergic disorders. Accurate
and prompt identification of the underlying cause is a key recommendation of several international guidelines, in order
to tailor treatment appropriately. Primary ciliary dyskinesia (PCD) is a genetic cause of bronchiectasis in which failure of
motile cilia leads to poor mucociliary clearance. Due to poor ciliary function in other organs, individuals can suffer from
chronic rhinosinusitis, otitis media and infertility.
This paper explores the current literature describing why, when and how to investigate PCD in adult patients with
bronchiectasis. We describe the main PCD diagnostic tests and compare the two international PCD diagnostic
guidelines. The expensive multi-test diagnostic approach requiring a high level of expertise and specialist equipment,
make the multifaceted PCD diagnostic pathway complex. Therefore, the risk of late or missed diagnosis is high and has
clinical and research implications.
Defining the number of patients with bronchiectasis due to PCD is complex. To date, few studies outlining the
aetiology of adult patients with bronchiectasis conduct screening tests for PCD, but they do differ in their
diagnostic approach. Comparison of these studies reveals an estimated PCD prevalence of 1–13% in adults with
bronchiectasis and describe patients as younger than their counterparts with moderate impairment of lung
function and higher rates of chronic infection with Pseudomonas aeruginosa.
Diagnosing PCD has clinical, socioeconomic and psychological implications, which affect patients’ life, including
the possibility to have a specific and multidisciplinary team approach in a PCD referral centre, as well as a genetic
and fertility counselling and special legal aspects in some countries.
To date no specific treatments for PCD have been approved, standardized diagnostic protocols for PCD and
recent diagnostic guidelines will be helpful to accurately define a population on which planning RCT studies to
evaluate efficacy, safety and accuracy of PCD specific treatments.
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Background
Bronchiectasis is a chronic respiratory disease characterized
by permanent dilatation of the bronchi and associated with
a clinical syndrome of cough, sputum production and re-
current respiratory infections, with attributable morbidity
and mortality rates [1, 2]. Although epidemiological data
are limited, recent literature suggests that bronchiectasis is
far from being a rare disease [3]. Different European data-
sets describe an increasing prevalence of bronchiectasis
with current rates estimated at 53 to 566 cases per 100,000
inhabitants [4–6]. Bronchiectasis represents the final path-
way of several infectious, genetic, immunologic or allergic
disorders which helps explain the extreme heterogeneity of
the disease [7]. Identifying the underlying cause both accur-
ately and quickly is a key recommendation of several inter-
national guidelines, as many aetiologies of bronchiectasis
are treatable or have specific prognostic implications [8].
Primary ciliary dyskinesia (PCD) is widely recognized
as an aetiology of bronchiectasis not only in children or
young adults but also in older patients [9–11]. PCD is a
rare disorder with an estimated prevalence of 1:10,000
[12] caused by mutations in more than 30 genes which
leads to functional and/or structural defects of motile
cilia [13, 14]. Cilia are specialized hair-like motile or
non-motile structures, containing nine pairs of microtu-
bules in a peripheral and radial distribution with a cen-
tral pair of microtubules. Motile ciliated epithelial cells
are present in the nasal cavity, paranasal sinuses, middle
ear, airways, fallopian tube, cervix, vas deferens and
ependyma. Respiratory cilia mediate the propulsion and
expulsion of the mucus layer through coordinated move-
ments (mucociliary clearance). PCD-causing mutations
result in immotile or ineffective ciliary beating and conse-
quently in abnormal mucociliary clearance and chronic
bacterial infection. This inflammatory and infectious
process leads to chronic rhinosinusitis and otitis media,
progressive airway obstruction, bronchiectasis and ultim-
ately respiratory failure [15]. In addition, failure of effect-
ive motile cilia function in the embryonic node leads to
situs inversus in ~ 50% patients with PCD. Sperm flagella
and cilia of the fallopian tubes share common axonemal
structures with motile cilia of the respiratory system, so
a proportion of PCD-affected males and females are
infertile [16].
Why is it important to diagnose PCD in adults
with bronchiectasis?
Although the optimal series of tests to investigate bron-
chiectasis aetiology is still under debate, most of the
clinical and scientific community underline the need to
investigate and diagnose PCD in adults with bronchiec-
tasis because of its clinical, social-economic and psycho-
logical implications. From a clinical perspective, PCD is a
multi-system disease with extra-respiratory involvement
which benefits from a specific, comprehensive and
multidisciplinary team approach in a PCD referral
centre [1, 17]. A prompt and accurate diagnosis should
be provided to patients because a late diagnosis is asso-
ciated with an impairment of respiratory function as
determined by decreased forced expiratory volume in
the 1st second (FEV1), and increased likelihood of
chronic Pseudomonas aeruginosa infection [18]. Fur-
thermore, PCD is a hereditary disorder and patients
and their families may require referral to genetic and
reproductive counselling services [17].
PCD therapeutic approach largely mimics treatment
for other chronic respiratory diseases such as cystic fi-
brosis (CF) and non-CF bronchiectasis. Chest physiother-
apy, including adjunct long-term mucoactive treatment
like nebulized hypertonic saline, and specific pulmonary
rehabilitation programmes are the cornerstones of PCD
long-term therapy [19], accompanied by prompt antibiotic
courses for exacerbations guided by historical sputum
cultures [17]. Moreover, upper airway involvement may
require a disease specific approach, including otolaryn-
gology and audiology counselling [17], as it delivers sig-
nificant symptom burden and puts patients at risk for
sinonasal infections and subsequent pulmonary exacer-
bations. Hearing aids may be indicated in a consider-
able number of adult PCD patients. Diagnostic nasal
sinus lavage for microbiologic sampling may be reason-
able, when chronic infection or inflammation of the
paranasal sinuses is suspected or when persistent rhino-
sinusitis is present. Daily sinonasal saline irrigation may
be required for the moisturisation of the nasal mucosa.
To date, no specific treatments for PCD are approved.
A multi-centre RCT of six-months azithromycin main-
tenance therapy is currently ongoing [20]. However, our
understanding of the molecular biology of PCD is
rapidly improving and in the near future we may see dif-
ferent treatment options for this group of patients. An
example of this is the current CLEAN-PCD trial
testing the VX-371 compound, an inhaled epithelial so-
dium channel (ENaC) inhibitor, that improves airway
hydration and mucociliary clearence blocking the re-
absorption of sodium in the airway surface liquid. The
CLEAN-PCD trial is an ongoing international, phase
II, randomized, double-blind, placebo-controlled study
to evaluate the safety and efficacy of VX-371 inhalation
with or without oral Ivacaftor in patients with PCD
(NCT02871778).
From a socioeconomic point of view, PCD patients
have access to free care and proper health insurance is-
sues in some countries and/or might benefit from special
legislation. From a psychological perspective, PCD is a
disabling chronic disease with implications for patients’
life plans. Most PCD patients, both male and female,
have an increased risk of fertility problems which may
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go undetected for a long time. Therefore, fertility coun-
selling should be included in PCD standard of care and
offered to patients when appropriate [16]. Finally, and
above all, patients wish to have a diagnosis and know
the reason for their symptoms [21].
When should PCD be investigated in adults with
bronchiectasis?
There are no publications which directly address whether
routine aetiological investigation protocols provide bene-
fits in terms of morbidity compared to clinically driven in-
vestigations or no testing. The recent guidelines published
by the European Respiratory Society (ERS) suggest a mini-
mum bundle of aetiological tests to be performed in adults
with a new diagnosis of bronchiectasis, including differen-
tial blood count, serum immunoglobulins and testing for
allergic bronchopulmonary aspergillosis [8]. Testing for
PCD is limited to patients with clinical features consist-
ent with the disease: persistent productive cough since
childhood, nasal polyposis and/or chronic rhinosinusi-
tis, chronic middle ear disease with or without hearing
loss, situs anomalies, congenital cardiac defects and a
history of neonatal respiratory distress or neonatal inten-
sive care admittance in term infants. These clinical factors
are included in the PICADAR score, a simple diagnostic
clinical tool to predict whether symptomatic patients have
PCD [22]. Most bronchiectasis guidelines agree with this
diagnostic approach targeted on patient clinical features,
underlining the importance of evaluating a history of
symptoms from upper and lower respiratory tract that
goes back to childhood [1, 8, 23]. However, some tertiary
referral centres with expertise in PCD testing investigate
PCD in most of their bronchiectasis patients [24, 25]. A
study shows how a full investigation of aetiologies in
adults with bronchiectasis allow diagnosis of PCD in
patients without a strong history consistent with the dis-
ease. In a cohort of 240 people presenting with chronic
productive cough and recurrent chest infections, PCD was
found in 17 (10%) patients with a mean age of 36 years
(36 ± 13) [11]. This suggests that the prevalence of PCD is
greater than is currently known and should be suspected
also in adults without typical PCD clinical features, in par-
ticular as clinical presentation may vary according to age.
How to diagnose PCD in adults with
bronchiectasis?
ERS guidelines propose a combination of tests to diag-
nose PCD, including nasal nitric oxide, high-speed video
analysis, transmission electron microscopy, immuno-
fluorescence and genetics. Due to poor sensitivity and
specificity of many of these modalities, multiple tests ra-
ther than a hierarchical strategy of testing are suggested
[8]. A short description of PCD diagnostic tests is pre-
sented below.
Clinical presentation
PICADAR and modified PICADAR
PICADAR is a simple diagnostic clinical tool to predict
whether patients with persistent productive cough are
likely to have PCD [22]. It has seven predictive parameters
(full-term gestation, neonatal chest symptoms, neonatal
intensive care admittance, situs inversus, congenital car-
diac defect, chronic rhinitis and ear symptoms) and each
contributes a weighted score (1–4) to give a maximum of
14 points. The best discriminative cut-off of the score is 5
points, with a sensitivity of 90% and a specificity of 75%.
PICADAR has a good accuracy and has already been vali-
dated internally and externally, with an Area Under the
Curve of 0.91 and 0.87, respectively. However, most adults
do not remember their gestational age or what hap-
pened immediately after their birth. Therefore, a modi-
fied PICADAR has been recently created to overcome
this problem: “gestational age” is omitted and “neonatal
chest symptoms” and “admittance to a neonatal unit”
are combined to a more general “neonatal respiratory
distress” [25]. Each parameter contributes again with 1
to 4 points to the total score, but the best discriminate
cut-off is 2, with a sensitivity of 100% and a specificity
of 89%. This modified score requires further prospect-
ive testing in adult cohorts.
Although both scores have easy and quick items to
compute and could be used to decide which patients to
refer to further PCD tests, they cannot be used in isola-
tion, because of their limited sensitivity and specificity.
In summary, suspicion based upon history and clinical
presentation is essential. Additional historical and clinical
features commonly observed in subjects with PCD include
parental consanguinity, pectus excavatum and scoliosis
[26, 27]. Chest high-resolution computer tomography
(HRCT) features can also be helpful in raising PCD suspi-
cion. Typical findings are the characteristic distribution,
extent and severity (predominantly middle and lower lobe
involvement) the presence of mucus plugging, tree in bud
phenomenon, atelectasis, history of middle or lower lobe
resection and situs inversus [28].
Nasal nitric oxide (nNO)
Measurement of nNO is one of the first steps in the
PCD diagnostic flowchart, because it is non-invasive, af-
fordable and relatively easy to perform, especially thanks
to the increasing availability of electrochemical portable
analyzers [29]. Therefore, nNO superseded saccharin test,
a previous test of nasal mucociliary clearance, no longer
advocated because it is not suitable for small children and
is prone to false positive and negative results [30].
Nasal NO is used in the PCD diagnostic algorithm be-
cause nNO levels are extremely low in most patients
with PCD when compared to healthy and disease con-
trols [31]. The reason behind this low nNO is unknown.
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Many hypotheses have been proposed so far, including a
reduced biosynthesis of nitric oxide (NO) by the airway
epithelium [32]; an increased breakdown of NO to me-
tabolites within respiratory cells or by denitrifying bac-
teria [33]; a reduced storage capacity of NO in the
paranasal sinuses [34] and NO trapped in the obstructive
paranasal sinuses [35], but none of them is unanimously
accepted.
There is also no consensus on the most appropriate
technique for velum closure, analyser sampling rate (to
which the measurement is sensitive) or what nNO
threshold constitutes a positive or negative cut-off [36].
Leigh and colleagues developed a threshold of 77 nL/min
using a conversion calculation which is reported to ac-
count for analyser differences with a sensitivity of 99% and
a specificity of 75% [37]; Beydon and co-workers used a
cut-off of 82 nL/min, reporting a sensitivity of 91% and a
specificity of 86% [38], whereas Jackson and colleagues
provided a sensitivity and specificity of 91 and 96%, re-
spectively, with a threshold of 30 nL/min [39]. To date,
77 nL/min is one the most used nNO cut-off and has been
accepted as a diagnostic criterion for PCD by the North
America PCD Foundation [17].
Many conditions though reduce nNO levels, including
nasal polyps [40], chronic sinusitis [41], diffuse pan-
bronchiolitis [42], cystic fibrosis (CF) [43], HIV infection
[44] and smoking [45]. In addition, PCD genotypes asso-
ciated with normal nNO levels have been increasingly
reported [46, 47]. Therefore, although the value of nNO
as part of the diagnostic algorithm for PCD is clear, its
lack of specificity prevents it from being used in isola-
tion to rule PCD in or out [36]. So, patient’s clinical his-
tory should be considered in conjunction with nNO
results when deciding whether to proceed with a nasal
brush biopsy [48].
High-speed video analysis (HSVA)
Ciliary function can be analyzed ex vivo by the assess-
ment of respiratory ciliary activity in epithelium obtained
by cytology brush from the nose or bronchus. A camera at-
tached to the microscope records at high speeds (120–500
frames per second – fps -) and video can be replayed slower
(30–60 fps) to measure ciliary beat frequency (CBF) and re-
view ciliary beat pattern (CBP) [49]. However, this requires
considerable expertise, and there is no consensus on appro-
priate cell processing and method of ciliary assessment.
Therefore, standardized protocols and thresholds need
to be developed for ex vivo analysis of CBF and CBP.
Ciliated cells can be observed immediately after sam-
pling and again after a period of culturing to differenti-
ate PCD from secondary dyskinesia, a ciliary defect
caused by infection and inflammation of the airways
[50]. Secondary ciliary dyskinesia can affect CBF (low
CBF) and CBP (poor coordination of ciliary beating,
lack of full sweep and mucus impedance) and therefore
repeating the analysis following cell culture in the pres-
ence of antibiotics is sometimes recommended to dif-
ferentiate it from a primary defect [36].
Transmission electron microscopy (TEM)
The evaluation of ciliary ultrastructural defects is a key
part of the diagnostic work-up. TEM is a highly specific
test, considered for many years the “gold standard” diag-
nostic test for PCD, because it can detect lack of dynein
arms [51], disorganizations of microtubular doublets
[52] or loss of the central microtubular pair [53]. How-
ever, TEM should not be used in isolation to exclude a
PCD diagnosis, because standardized protocols and con-
sensus on terminology, especially regarding the number
and proportion of cilia required to make a diagnosis, are
lacking and 15–30% of patients with PCD have apparently
normal ciliary ultrastructure, for example those with a
pathogenic variant in DNAH11 [36, 54]. It is important to
underline that acquired defects can be associated with
transient ultrastructural abnormalities (disrupted mem-
branes, compound cilia, additional tubules and axonemal
blebs) [50], so repeating TEM after cell culture may be
helpful in equivocal cases.
Immunofluorescence
Immunofluorescence (IF) can help confirm PCD using
fluorescent antibodies to stain ciliated respiratory epi-
thelium obtained by nasal brushing. IF can detect the
absence of key ciliary proteins such as the DNAH5
heavy chain of the outer dynein arm [55]. IF may iden-
tify some cases where TEM is apparently normal or
subtly abnormal [56, 57] and it is cheaper and quicker
than TEM, but, although its accuracy has recently been
determined, its sensitivity remains limited [58]. Many
PCD mutations and structural cilia proteins have not
been identified yet and false negative results may
occur, but gene discovery and antibody development
are likely to improve immunofluorescence sensitivity
and technique.
Genetics
Genetic testing for disease-causing mutations can be
performed in patients suspected of having PCD to
confirm the diagnosis such as those with normal ultra-
structure by TEM or in already confirmed PCD pa-
tients to provide a genetic diagnosis. Non-ambiguous
bi-allelic autosomal mutations or hemizygous X-linked
mutations are identified in 50–75% of cases [59]. To
date, more than 1000 disease causing variants across
more than 35 genes have been described and the most
common are in the dynein heavy chains DNAH5 and
DNAH11 [60]. However, not all PCD mutations are
known and accuracy of genetic testing is still lacking.
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Diagnostic testing guidelines
Currently there are two specific PCD guidelines that
propose diagnostic criteria and describe diagnostic tests:
the guidelines published by ERS [36] and the consensus
recommendations published by the North American
PCD Foundation [17]. They differ in many aspects. First
of all, ERS guidelines are evidence-based guidelines,
whereas the American Genetic Disorders of Mucociliary
Clearance Consortium (GDMCC) created a consensus
statement. The American recommendations distinguish
PCD diagnostic criteria by age and define PCD diagnosis
according to the presence of two or more major clinical
criteria (unexplained neonatal respiratory distress, any
organ laterality defects, chronic wet cough and rhinosi-
nusitis since childhood) plus at least one positive diagnos-
tic test (nNO, HSVA, TEM and genetics). ERS, instead, do
not distinguish PCD diagnostic criteria by age, but provide
a diagnostic algorithm with a step-wise approach ending
in different outcomes: PCD positive, PCD highly likely
and PCD extremely unlikely.
The two publications differ also in some diagnostic test
aspects. The American statement recommends 77 nL/min
as nNO threshold, whereas ERS guidelines cannot find a
consensus on the appropriate nNO cut-off. ERS guidelines
recommend the use of HSVA before and after cellular
culture as an important diagnostic tool, while the Ameri-
can statement, although recognizing its importance, un-
derlines the fact that few centres have expertise to
perform these tests.
The ERS guidelines and the American statement share
also some similarities: both include infants and adults;
both could not recommend IF as a diagnostic tool be-
cause studies were lacking, although these studies have
now been performed [58] and both advise against the use
of TEM in isolation to exclude PCD because some pa-
tients with PCD show apparently normal ultrastructure.
The comparison between the two publications is sum-
marized in Table 1.
Prevalence of PCD in adults with bronchiectasis
Defining the prevalence of PCD in adults with bronchi-
ectasis is challenging.
Some epidemiological information comes from papers
that, despite having other aims, describe adult bronchiec-
tasis populations and briefly their aetiologies, including
ciliary dysfunction [61–68].
Other studies are focused on defining the demographic
characteristics and identifying the aetiologies of patients
with bronchiectasis, but do not describe the criteria used
to diagnose PCD [69–73], or do not describe any PCD
Table 1 A comparison between European Respiratory Society (ERS) and North American primary ciliary dyskinesia (PCD) Foundation
guidelines
ERS 2017 [36] North American PCD Foundation 2016 [17]
Structure Evidence-based guidelines Consensus statement
Patients included Infants and adults Infants and adults
Diagnostic criteria distinguished by age Not done Newborns (0–1 month)
Children (1 month – 5 years)
Children 5–18 years and adults
Diagnostic criteria A diagnostic algorithm is proposed Two major clinical criteria PLUS at least one
diagnostic test
Diagnostic outcome PCD positive, PCD highly likely and PCD
extremely unlikely
PCD positive and PCD negative
nNO No consensus on appropriate thresholds < 77 nL/min on 2 occasions, > 2 months apart,
with CF excluded
HSVA Several European centres employ HSVA due to
high expertise
No American centres can reliably perform HSVA
due to lack of expertise
Cell culture Recommended to improve accuracy of HSVA and
TEM to rule out a false positive diagnosis or
support a highly likely diagnosis
Not mentioned
IF Not included in the diagnostic algorithm due to
lack of studies at time of guideline
Not included in the diagnostic criteria due to
lack of studies at time of guideline
TEM Can be used to confirm a diagnosis but advise
against TEM in isolation to exclude PCD because
some patients with PCD have apparently normal
ultrastructure
Can be used to confirm a diagnosis but advise
against TEM in isolation to exclude PCD because
some patients with PCD have apparently normal
ultrastructure
Genotyping Can be used to confirm a diagnosis but cannot
be used to exclude a diagnosis because evidence
on sensitivity and specificity lacks
Can be used to confirm a diagnosis but cannot
be used to exclude a diagnosis because evidence
on sensitivity and specificity lacks
PCD Primary ciliary dyskinesia, nNO Nasal nitric oxide, CF Cystic fibrosis, HSVA High-speed video analysis, IF Immunofluorescence, TEM Transmission electron microscopy
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patients in their cohorts [74–76]. To our knowledge,
two retrospective studies and ten prospective studies
outline the aetiology of adults with bronchiectasis and
conduct screening tests for PCD [11, 24, 77–86]. As
regards the PCD diagnostic approach though, they differ
in many aspects. Most studies use clinical features and
history of upper and lower respiratory symptoms and/or
infertility as a PCD screening method for further testing
[24, 77, 78, 81–83, 85, 86], while one study performs
chest high-resolution computed tomography (HRCT) to
find diffuse bronchiectasis, considering it a characteristic
to investigate for PCD [79].
The studies differ also in the selection of further
tests: saccharin test alone [83]; saccharin test and/or
nNO [24, 85]; saccharin test, NO test or nasal muco-
ciliary clearance by sero-albumin [86]. Finally, TEM
[79, 82, 85], ciliary function [81] or referral patients to
a PCD centre [24, 82] are chosen as diagnostic ap-
proach to confirm PCD.
Three studies test all adult bronchiectasis patients for
PCD, but again they select different assessments: sac-
charin test [84], saccharin test plus nNO [11] and light
microscopy for the CBF [80] as first steps; TEM [80],
HSVA plus TEM [11] and Kartagener’s features [84] to
confirm PCD diagnosis.
In all the mentioned studies PCD prevalence varies
from 1 to 13% in adults with bronchiectasis, but
different screening tools and diagnostic tests make this
assessment quite difficult to interpret. It will be of
interest to see the effect of the recently published
diagnostic guidelines on the approach to such studies
going forward.
Some of the prospective studies describe the resultant
PCD cohort. PCD patients who have been identified are
younger than other bronchiectasis patients [11, 24, 84, 86],
without differences in gender prevalence and non-smokers
[24, 86]. They have a higher prevalence of bilateral
bronchiectasis (48.3%) and a moderate impairment of
FEV1 (67.1% ± 24.2) [86]. PCD patients have higher
rates of chronic infection with P. aeruginosa (45%) and
are treated with chronic inhaled antibiotic more fre-
quently (39.6%) when compared with other patients
with bronchiectasis [86].
The comparison between the publications is summa-
rized in Table 2.
PCD published studies are few with low numbers of
patients involved. Recently, two large international
registries (iPCD Cohort and International PCD registry)
have been created, including over 3000 PCD patients
[9, 10]. Although these registries have the strength of
assessing differences in PCD characteristics and man-
agement between countries and ethnic groups, they
have also some limitations in defining what a positive
diagnosis of PCD is. They also have a predominance of
paediatric patients, suggesting adults with PCD are be-
ing neglected from a research perspective.
Conclusion
Physicians treating bronchiectasis patients should sus-
pect the diagnosis of PCD in adults, in order to offer
appropriate care. The requirement for a multi-test diag-
nostic approach where some tests are very expensive,
some requiring a high level of expertise and specialist
equipment, make the multifaceted PCD diagnostic path-
way complex. Therefore, the risk of heterogeneous, late or
missed diagnosis is high [9, 18] and has clinical and re-
search implications. Standard diagnostic protocols for
PCD will be helpful to accurately define a population on
which planning RCT studies to evaluate efficacy, safety
and accuracy of treatments.
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